loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Rainbow Childrens Medicare Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Rainbow Childrens Medicare Ltd. 13 Nov 2025 18:35 PM
Result PDF

Q2FY26 Quarterly Result Announced for Rainbow Childrens Medicare Ltd.

Healthcare Facilities company Rainbow Childrens Medicare announced Q2FY26 results

  • Revenue: Rs 4,448.0 million against Rs 4,174.6 million during Q2FY25, change 6.5%.
  • EBITDA: Rs 1,488.7 million against Rs 1,470.8 million during Q2FY25, change 1.2%.
  • EBITDA Margin: 33.5% for Q2FY26.
  • PAT: Rs 756.2 million against Rs 790.1 million during Q2FY25, change -4.3%.
  • PAT Margin: 17.0% for Q2FY26.

Ramesh Kancharla, Chairman & Managing Director of Rainbow Children’s Medicare, said: “While Q2 was seasonally softer, it was also a quarter of strategic progress for Rainbow. We completed our first acquisition in the Northeast, launched Rainbow at Rajahmundry, and are set to open two more hospitals in Bengaluru shortly. With a significant part of our expansion now complete, our focus will move toward strengthening business operations and driving sustainable growth across our network.”

Result PDF

Result PDF

Healthcare Facilities company Rainbow Childrens Medicare announced Q1FY26 results

  • Revenue grew by 6.9%, from Rs 3,302.2 million in Q1FY25 to Rs 3,529.3 million in Q1FY26.
  • EBITDA grew by 10.6%, from Rs 937.2 million in Q1FY25 to Rs 1,036.2 million in Q1FY26.
  • EBITDA % increased by 98 bps, from 28.4% in Q1FY25 to 29.4% in Q1FY26.
  • PAT grew by 35.4%, from Rs 397.3 million in Q1FY25 to Rs 538.1 million in Q1FY26.
  • PAT % increased by 321 bps, from 12.0% in Q1FY25 to 15.2% in Q1FY26.

Ramesh Kancharla, Chairman & Managing Director of Rainbow Children’s Medicare, said: “The first quarter followed typical seasonal trends, particularly in general pediatrics and pediatric intensive care, as seen in some of our mature hospitals. However, we’re encouraged by the continued momentum in our newer facilities, which are scaling up well and contributing meaningfully to our overall growth trajectory. We’re also seeing sustained growth in our tertiary and quaternary care offerings, reaffirming our strategic focus on building depth in tertiary and quaternary pediatrics care.

Welcoming Prashanthi Hospital, Warangal, into our network stands as a significant step as we extend our reach into promising Tier 2 regions.

Looking ahead, our key priorities include advancing clinical capabilities, reinforcing operational excellence, and ensuring the on-schedule launch of our new hospitals. We remain confident that the strength of our care model, the expertise of our teams, and our disciplined execution together will allow us to deliver accessible, high-quality healthcare for mothers and children across geographies.”

Result PDF

Healthcare Facilities company Rainbow Childrens Medicare announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue rose by 8.5% to Rs 3,701.1 million from Rs 3,411.0 million.
  • EBITDA increased by 8.7% to Rs 1,147.3 million from Rs 1,055.4 million.
  • EBITDA Margin improved by 6 bps to 31.0% from 30.9%.
  • PAT grew by 10.7% to Rs 565.5 million from Rs 510.7 million.
  • PAT Margin expanded by 31 bps to 15.3% from 15.0%.

FY25 Financial Highlights:

  • Revenue grew by 16.9% to Rs 15,158.7 million from Rs 12,969.0 million.
  • EBITDA rose by 14.2% to Rs 4,898.9 million from Rs 4,288.8 million.
  • EBITDA Margin declined by 75 bps to 32.3% from 33.1%.
  • PAT increased by 11.9% to Rs 2,442.3 million from Rs 2,182.9 million.
  • PAT Margin contracted by 72 bps to 16.1% from 16.8%.

Speaking about the performance for Q4FY25, Ramesh Kancharla, Chairman & Managing Director of Rainbow Children’s Medicare , said: “On the operational front, our performance in Q4 is seasonally muted when compared to the stronger results delivered in the second and third quarters of the year. In Q4FY25, our revenue stood at Rs 3,701.1 million, reflecting a year-on-year increase of 8.5% from Rs 3,411 million in Q4FY24. Our EBITDA reached Rs 1,147.3 million, up 8.7% from Rs 1,055.4 million, while our PAT rose 10.7% to Rs 565.5 million from Rs 510.7 million in the same period last year.

With a network of over 2,000 beds, including managed facilities, we have a well-balanced mix of established and emerging hospitals. Our immediate focus remains on improving occupancy levels, streamlining operations, and upholding our commitment to exceptional patient care. With this strong foundation in place, I remain confident in our continued growth and success in the quarters ahead”

Result PDF

Healthcare Facilities company Rainbow Childrens Medicare announced Q3FY25 results

  • Revenue: Rs 3,980.8 million compared to Rs 3,359.6 million during Q3FY24, change 18.5%.
  • EBITDA: Rs 1,343.6 million compared to Rs 1,180.8 million during Q3FY24, change 13.8%.
  • EBITDA margin: 33.8% for Q3FY25.
  • PAT: Rs 689.4 million compared to Rs 625.7 million during Q3FY24, change 10.2%.
  • PAT margin: 17.3% for Q3FY25.

Ramesh Kancharla, Chairman & Managing Director, Rainbow Children’s Medicare, said: “I’m pleased to share that we had a strong performance this quarter, with significant growth across all our hospitals. Our revenue for Q3FY25 was Rs 3,980.8 million, a remarkable increase of 18.5% from Rs 3,359.6 million in Q3FY24. Our EBITDA for the quarter reached Rs 1,343.6 million, showing strong growth of 13.8% compared to Rs 1,180.8 million in Q3FY24. Our PAT for Q3FY25 was Rs 689.4 million, an impressive rise of 10.2% from Rs 625.7 million in Q3FY24.

With a network of over 2,000 beds, including managed facilities, we strike the perfect balance between established and new hospitals. Our focus is on boosting occupancy, optimizing operations, and providing exceptional experiences for our patients. Looking ahead, we're confident in our continued growth and success in the coming quarters.”

Result PDF

Healthcare Facilities company Rainbow Childrens Medicare announced Q2FY25 results

  • Revenue: Q2FY25: Rs 4174.6 million QoQ change 26.4%; Q1FY25: Rs 3302.2 million.
  • EBITDA: Q2FY25: Rs 1470.8 million QoQ change 56.9%; Q1FY25: Rs 937.2 million.
  • EBITDA %: Q2FY25: 35.2% QoQ change 685bps; Q1FY25: 28.4%.
  • PAT: Q2FY25: Rs 790.1 million QoQ change 98.9%; Q1FY25: Rs 397.3 million.
  • PAT %: Q2FY25: 18.9% QoQ change 689bps; Q1FY25: 12.0%,.

Ramesh Kancharla, Chairman & Managing Director of Rainbow Children’s Medicare Limited, said: “ I am delighted to share that we have delivered a strong performance this quarter led by robust volume growth across all hospitals. Our revenue for Q2FY25 reached Rs 4,174.6 million marking a robust 25.5% increase from Rs 3326.8 million in Q2FY24. Our EBITDA for the quarter was Rs 1,470.8 million, reflecting a growth of 25.1% compared to Rs 1,175.6 million in Q2FY24. The PAT for Q2FY25 was Rs 790.1 million, an increase of 25.1% from Rs 631.6 million in Q2FY24.

We currently have 2000 beds, including the managed beds, with a right mix of matured and new beds. Our focus remains to drive occupancies and optimize operations across the group along with customer delight. We are confident in our ability to maintain the growth momentum in the upcoming quarters.”

Result PDF

Healtcare Facilities company Rainbow Childrens Medicare announced Q1FY25 results:

  • Revenue: Rs 3,302.2 million, up 15.0% YoY, down 3.2% QoQ. 
  • EBITDA: Rs 937.2 million, up 6.9% YoY, down 11.2% QoQ.
  • EBITDA Margin: 28.4%, down 216 basis points YoY and 256 basis points QoQ.
  • PAT: Rs 397.3 million, down 4.2% YoY, down 22.2% QoQ.
  • PAT Margin: 12.0%, down 242 basis points YoY and 294 basis points QoQ.

Commenting on the Performance for Q1 FY25, Ramesh Kancharla, Chairman & Managing Director of Rainbow Children’s Medicare, said: “I am delighted to share that we have delivered a strong performance this quarter. Our revenue for Q1 FY25 reached Rs 3,302 million, marking a robust 15% increase from Rs 2,872 million in Q1 FY24. Our EBITDA for the quarter was Rs 937 million, reflecting a growth of 6.9% compared to Rs 877 million in Q1 FY24. Although our PAT for Q1 FY25 was Rs 397 million, a decrease of 4.2% from Rs 415 million in Q1 FY24, this is attributable to the initial costs associated with our new hospitals.

We currently have 2000 beds including the managed beds, with a right mix of matured and new beds. Our focus remains to drive occupancies and optimize operations across the group along with custromer delight. We are confident in our ability to drive growth in the upcoming quarters.”

Result PDF

Healthcare Facilities company Rainbow Childrens Medicare announced Q4FY24 & FY24 results:

  • Board recommends final dividend of 30% per Equity Share of Face Value Rs 10 amounting to Rs 304.5 million [Dividend Rs 3 per equity share]
  • Project Status update:
    • Development of the spoke hospital at Hennur, Bengaluru (~60 beds) and the regional spoke hospital at Rajahmundry (~100 beds) is progressing well and will be completed in the next 12 months. Both the hospitals are likely to commence operations in Q4FY25.
    • For the regional spoke hospital at Coimbatore, the project work has just started and is expected to commence operations in 24 months.
  • The company has received the possession letter for the land parcels at Gurugram at sector 44 and 56 respectively. The company expects the ground breaking in next 3-4 months.
  • The company continued to have strong balance sheet and have cash & cash equivalent, fixed deposits and mutual fund investments aggregating to Rs 5,159 million as of March 31, 2024, which will be deployed for the ongoing capex plan of the company. Based on the present cash flow and expected internal accrual in the coming years, the company expects to complete all the planned capex with internal accruals and balance IPO funds.
  • During the quarter, company has spent Rs 504 million for the capex.

Commenting on the performance for Q4FY24 Dr. Ramesh Kancharla, Chairman & Managing Director, Rainbow Children’s Medicare said, “We had a significant quarter with three new hospitals commissioned in a span of three months. Our project and operations team have worked exceedingly well to ensure that all the projects were commissioned on time. With major expansion completed, we are solely focused on building and strengthening operations at newly commissioned hospitals and add services at existing units to propel them to new areas of growth”

Result PDF

Healthcare Facilities company Rainbow Childrens Medicare announced Q3FY24 results:

Financial Performance:

  • Revenue: Rs 3,359.6 million, marking a YoY growth of 9.6% compared to Rs 3,064.0 million in Q3FY23.
  • EBITDA: Achieved Rs 1,180.8 million with a 10.6% increase from Rs 1,067.6 million in the same quarter the previous year. EBITDA margin was at 35.1%.
  • Profit After Tax (PAT): Grew by 7.4%, reaching Rs 625.7 million from Rs 582.4 million in Q3FY23, with PAT margin reporting a slight dip by 38 bps to 18.6%.

Operational Highlights:

  • Capacity and Beds: Expanded to 1,655 operational beds, a 6% increase from 1,555 beds in Q3FY23.
  • Occupancy Rate: Experienced a decrease to 50.8%, a 630 bps drop from 57.1% in Q3FY23.
  • Inpatient Discharges: Slightly increased to 22,888 from 22,665 YoY.
  • Outpatient Consultations: Small growth to 3,17,146 consultations, up from 3,15,485 in the same quarter last year.
  • Deliveries: Witnessed an uptick to 4,127 deliveries compared to 4,019 previously.
  • Average Revenue Per Occupied Bed (ARPOB): Stood at Rs 55,768.
  • Average Length of Stay (ALOS): Reduced slightly to 2.63 days from 2.77 days YoY.

New Developments and Expansion:

  • Commissioned the 8th hospital in Hyderabad with 60 beds.
  • Ongoing projects include the finalization of hospitals in Anna Nagar, Chennai, and Sarjapur Road, Bangalore, expected to commence in Q4FY24.
  • Continued development in Hennur, Bangalore, and Rajahmundry, with expected completion in the next 12-15 months.
  • Acquired two land parcels in Gurgaon for future expansion.

 

Commenting on the performance for Q3FY24, Dr. Ramesh Kancharla, Chairman & Managing Director, Rainbow Children’s Medicare, said, “ I'm delighted to announce that our company has showcased a resilient operating and financial performance this quarter. The revenue for Q3FY24 was Rs 3,359.6 million, which is a growth of 9.6% compared to Rs 3,064.0 million in Q3FY23. The EBIDTA for Q3FY24 was Rs 1,180.9 million, which is a growth of 10.6% compared to Rs 1,067.6 million in Q3FY23 and the PAT for Q3FY24 was Rs 625.7 million, which is a growth of 7.4% compared to Rs 582.4 million in Q3FY23.

We have managed to fortify our operations and deliver stable performance despite the continued seasonal headwinds. Our operating performance reflects our commitment to delivering high-quality healthcare to our patients.

We remain dedicated to the timely execution and initiation of our projects and add 280 beds during the current financial year.

The company continues its unwavering dedication to its mission: to provide outstanding multi-disciplinary pediatric and perinatal care. We are constantly refining our services to serve our patients."

 

 

Result PDF

Healthcare Facilities company Rainbow Children's Medicare announced Q4FY23 & FY23 results:

  • Q4FY23 vs Q4FY22:
    • Revenue: Rs 3,169.66 million vs Rs 2,124.47 million, up 49.20% YoY
    • EBITDA: Rs 980.07 million vs Rs 481.33 million, up 103.62% YoY
    • EBITDA %: 30.92% vs 22.66%, up 826 bps YoY
    • PAT: Rs 538.63 million vs Rs 122.60 million, up 339.34% YoY
    • PAT %: 16.99% vs 5.77%, up 1,122 bps YoY
  • FY23 vs FY22:
    • Revenue: Rs 11,735.74 million vs Rs 9,737.58 million, up 20.52% YoY
    • EBITDA: Rs 3,963.77 million vs Rs 3,048.75 million, up 30.01% YoY
    • EBITDA %: 33.78% vs 31.31%, up 247 bps YoY
    • PAT: Rs 2,123.77 million vs Rs 1,386.73 million, up 53.15% YoY
    • PAT %: 18.10% vs 14.24%, up 386 bps YoY

Commenting on the performance for Q4FY23, Dr. Ramesh Kancharla, Chairman & Managing Director, Rainbow Children’s Medicare (RCML), said, “I am pleased to inform you that the company has delivered robust quarterly performance, led by high patient footfall across hospitals. The revenues for Q4FY23 were Rs 3,169.66 million, which is a growth of 49.20% compared to Rs 2,124.47 million in Q4FY22. The EBIDTA for Q4FY23 was Rs 980.07 million, which is a growth of 103.62% compared to Rs 481.33 million in Q4FY22, and the PAT for Q4FY23 was Rs 538.63 million, which is a growth of 339.34% compared to Rs 122.60 million in Q4FY22.

The company is focused on executing the business plan, put forth during the IPO, of adding 1000 beds across the target markets. The proposed expansion for the current financial year includes the addition of ~270 beds in Central Hyderabad (60 beds), Hydernagar (50 beds), Anna Nagar (80 beds), and Sarjapur (80 beds). Additional ~160 beds are slated for commencement in the next financial year at Rajahmundry (100 beds) and a new spoke hospital in Bengaluru (60 beds). Furthermore, the company aims to increase its bed count by ~400 across the National Capital Region by FY26-27.

The company remains committed to fulfilling its mission of delivering excellent multi-disciplinary pediatric and perinatal care and strives to enhance its service offerings by making constant improvements.”

 

 

 

Result PDF

Rainbow Children Medicare announced Q3FY23 results:

  • Q3FY23:
    • Revenues for Q3FY23 stood at Rs 3,064.04 million, growth of 23.17% compared to Rs 2,487.56 million in Q3FY22.
    • EBIDTA for Q3FY23 was Rs 1,067.56 million, growth of 19.59% compared to Rs 892.68 million in Q3FY22
    • PAT for Q3 FY23 was Rs 582.44 million, growth of 28.87% compared to Rs 451.95 million in Q3FY22.

Commenting on the performance for Q3FY23, Ramesh Kancharla, Chairman & Managing Director, Rainbow Children’s Medicare Limited (RCML), said, “I am pleased to inform you that the company has delivered robust quarterly performance, led by high patient footfalls across hospitals in every geography.

We are pleased to share that the projects which are under execution are progressing well and will commence operations within the targeted timelines.”

 

Result PDF

Trending News

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

L&T's Buildings & Factories (B&F) business has won multiple large domestic EPC orders across tourism

L&T's Buildings & Factories (B&F) business has won multiple large domestic EPC orders across tourism

Published on 18-Dec-2025 09:03

Marico has amended the definitive agreements to extend the timeline for acquiring the remaining 40% stake in Satiya Nutraceuticals (PLIX) by 12 months

Marico has amended the definitive agreements to extend the timeline for acquiring the remaining 40% stake in Satiya Nutraceuticals (PLIX) by 12 months

Published on 18-Dec-2025 09:01

Axis Bank MD & CEO Amitabh Chaudhry said that recent RBI rate cuts will delay stabilisation of net interest margins

Axis Bank MD & CEO Amitabh Chaudhry said that recent RBI rate cuts will delay stabilisation of net interest margins

Published on 18-Dec-2025 09:00

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status